The relationship of NT-proBNP and dialysis parameters with outcome of incident haemodialysis patients: Results from the membrane permeability outcome study for the Membrane Permeability Outcome (MPO) study group

Blood Purification

Volumn 35, Issue 1-3, 2013, Pages 216-223

  Locatelli, Francesco ^a   Hannedouche, Thierry ^b   Martin Malo, Alejandro ^c   Jacobson, Stefan H ^d   Vanholder, Raymond ^e   Ronco, Claudio ^f   La Milia, Vincenzo ^a   Lopez Gomez, Juan M ^g   Stefoni, Sergio ^h   Maheut, Hervé ⁱ   Klinger, Marian ^j   Krummel, Thierry ^b   Dhondt, Annemie ^e   Berdud, Isabel ^c   Gauly, Adelheid ^k  

^a A MANZONI HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d DANDERYD HOSPITAL   (Sweden)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f SAN BORTOLO HOSPITAL   (Italy)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ REIMS UNIVERSITY HOSPITAL   (France)

^j WROCLAW MEDICAL UNIVERSITY   (Poland)

^k Clinical Research   (Germany)

more..

Author keywords

BNP; Cardiovascular diseases; Haemodialysis; High flux membrane; Mortality; NT proBNP; Randomised trials

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); ARTIFICIAL MEMBRANE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; AGED; ARTIFICIAL MEMBRANE; BLOOD; CONTROLLED CLINICAL TRIAL; KIDNEY FAILURE; MIDDLE AGED; MULTICENTER STUDY; PERMEABILITY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; RENAL INSUFFICIENCY;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERMEABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84875636568     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000347076     Document Type: Article

References (28)

1. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
2. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
3. Wang AY, Lai KN: Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008; 19: 1643-1652.
4. Weber M, Hamm C: Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843-849.
5. Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, van Veldhuisen DJ, Gans RO, de Zeeuw D: N-terminal pro-Btype natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 2010; 31: 120-127.
6. de Lemos JA, McGuire DK, Drazner MH: Btype natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322.
7. Locatelli F, Eckardt KU, Macdougall IC, Tsakiris D, Clyne N, Burger HU, Scherhag A, Drueke TB: Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study. Curr Med Res Opin 2010; 26: 2543-2552.
8. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548-554.
9. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-1515.
10. Kamano C, Osawa H, Hashimoto K, Nishimura S, Saito SK, Kashiwagi T, Iino Y, Katayama Y: N-Terminal pro-brain natriuretic peptide as a predictor of heart failure with preserved ejection fraction in hemodialysis patients without fluid overload. Blood Purif 2012; 33: 37-43.
11. Krupicka J, Janota T, Kasalova Z, Hradec J: Nat riuretic peptides -physiology, pathophysiology and clinical use in heart failure. Physiol Res 2009; 58: 171-177.
12. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O: Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol 2010; 99: 445-452.
13. Codognotto M, Piccoli A, Zaninotto M, Mion MM, Ruzza L, Barchita A, Naso A, Plebani M: Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol 2010; 23: 465-471.
14. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J: Brain natriuretic peptide and N-terminal pro-BNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103:c162-c172.
15. Sommerer C, Heckele S, Schwenger V, Katus HA, Giannitsis E, Zeier M: Cardiac biomarkers are influenced by dialysis characteristics. Clin Nephrol 2007; 68: 392-400.
16. Wahl HG, Graf S, Renz H, Fassbinder W: Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and Nterminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071-1074.
17. Rosner MH: Measuring risk in end-stage renal disease: is N-terminal pro brain natriuretic peptide a useful marker? Kidney Int 2007; 71: 481-483.
18. Sun L, Sun Y, Zhao X, Xu C, Chen D, Li L, Ma Y, Rong S, Mei C: Predictive role of BNP and NT-proBNP in hemodialysis patients. Nephron Clin Pract 2008; 110:c178-c184.
19. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R: The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999; 12: 85-88.
20. van der Merwe DE, Henley R, Lane G, Field R, Frenneaux M, Dunstan F, McDowell I: Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. Clin Chem 2004; 50: 779-780.
21. de Mutsert R, Jager KJ, Zoccali C, Dekker FW: The effect of joint exposures: examining the presence of interaction. Kidney Int 2009; 75: 677-681.
22. Koch M, Trapp R, Kohnle M, Aker S, Haastert B, Rump LC: B-type natriuretic peptide and severe heart failure at baseline predict overall mortality in incident dialysis patients. Clin Nephrol 2010; 73: 21-29.
23. Chazot C, Vo-Van C, Zaoui E, Vanel T, Hurot JM, Lorriaux C, Mayor B, Deleaval P, Jean G: Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Nephrol Dial Transplant 2011; 26: 2630-2634.
24. Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Christensen JH: NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol 2009; 71: 380-386.
25. Paniagua R, Ventura MD, Avila-Diaz M, Hinojosa-Heredia H, Mendez-Duran A, Cueto-Manzano A, Cisneros A, Ramos A, Madonia-Juseino C, Belio-Caro F, Garcia-Contreras F, Trinidad-Ramos P, Vazquez R, Ilabaca B, Alcantara G, Amato D: NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010; 25: 551-557.
26. Alsuwaida A: Influence of erythropoietin dose and albumin level on the plasma brain natriuretic peptide in hemodialysis patients. Saudi J Kidney Dis Transpl 2006; 17: 171-176.
27. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr: Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-982.
28. Guo Q, Barany P, Qureshi AR, Snaedal S, Heimburger O, Stenvinkel P, Lindholm B, Axelsson J: N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. Am J Nephrol 2009; 29: 516-523.